Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Retatrutide

LY3437943, LY-3437943

Quick Stats
Studies 83
Trials 32
Completed PHASE1 INTERVENTIONAL NCT05757531

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.

Interventions

Name: [¹⁴C]-LY3437943
Type: DRUG
Description: Administered SC.

Primary Outcomes

Measure: Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
TimeFrame: Predose up to 63 days post dose
Description: Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Measure: Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
TimeFrame: Predose up to 63 days post dose
Description: Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Trial Information

NCT ID

NCT05757531

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Eli Lilly and Company

Last Updated

December 15, 2025